Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

A hair transplant experienced by FC Barcelona goalkeeper Ter Stegen, who reportedly saw improved confidence and performance following the procedure. People discussed finasteride as an alternative treatment option for those unable to afford a transplant.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

The user started treating their slightly thinning, receded hairline with a serum containing Redensyl and other ingredients, and dermarolling weekly. They recently began taking finasteride and plan to stop Redensyl in the future to test if hair loss resumes.

The conversation discusses struggles with diffuse thinning and hair loss treatments, including the use of dutasteride, minoxidil, and finasteride, with limited success. The original poster regrets having a hair transplant at 21 due to weak donor hair and ongoing thinning.

A user is making a homemade topical finasteride solution by dissolving crushed finasteride tablets in ethanol and PG. They are unsure if the final solution maintains the intended concentration after filtering and are considering adding more ethanol to ensure accuracy.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

A 28 year old male experiencing diffuse thinning, chronic dandruff and scalp crust (seborrheic dermatitis), with replies discussing the use of topical fin for hormone imbalances and Nizoral for seb derm.

User discusses Alfatradiol (17a-Estradiol) as a potential hair loss treatment with mixed results. Concerns include low dosage, receptor theory, and possible increased aromatase activity on scalp.

An international student in Germany needs a prescription for finasteride and minoxidil to continue treating androgenic alopecia. They seek guidance on finding a doctor and using their student health insurance for the prescription.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Eucapil (fluridil) is approved as a cosmetic hair-care agent in Europe, but users question the level of testing required for approval.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

The conversation discusses the effectiveness and authenticity of RU58841 purchased from Amazon, with some users suggesting buying from reputable sources like Anagen Inc. Others recommend using oral finasteride instead of RU58841 due to concerns about product legitimacy.

A dermatologist recommended PRP (Platelet Rich Plasma) and GFC (Growth Factor Concentrate) for pattern baldness, but online sources suggest they may not be effective. The user is seeking opinions on these treatments.

A 49-year-old is documenting their hair regrowth journey using tretinoin cream, minoxidil foam, and finasteride. They report thicker hair and improved confidence, though progress feels slow and mentally challenging.

RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

The user has been using minoxidil foam and a dermaroller for three months to combat hair loss, with noticeable progress. They are seeking finasteride but face difficulties obtaining it in Germany.

Hair cloning may become available in 1-2 years in Japan, but widespread availability and affordability could take 7-15 years. Current treatments like finasteride are effective but may lose effectiveness over time.

RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.